Expression of soluble adenylyl cyclase in lentigo maligna use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 12, 2012, Pages 1558-1564

  Magro, Cynthia M ^a   Yang, Sung Eun ^b   Zippin, Jonathan H ^a   Zembowicz, Artur ^c,d,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^e Department of Pathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; MELAN A; MONOCLONAL ANTIBODY; R21 MONOCLONAL ANTIBODY; TUMOR MARKER; TUMOR PROTEIN;

ANTIBODY SPECIFICITY; CELL NUCLEUS; CHEMISTRY; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALIGNANT LENTIGO; MELANOCYTE; MELANOMA; METABOLISM; MULTICENTER STUDY; NEVUS; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SKIN; SKIN TUMOR; SOLUBILITY; VALIDATION STUDY;

ADENYLATE CYCLASE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL NUCLEUS; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MART-1 ANTIGEN; MELANOCYTES; MELANOMA; NEOPLASM PROTEINS; NEVUS; SENSITIVITY AND SPECIFICITY; SKIN; SKIN NEOPLASMS; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84870876193     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0617-OA     Document Type: Conference Paper

References (23)

1. Park HY, Gilchrest BA. Signaling pathways mediating melanogenesis [review]. Cell Mol Biol (Noisy-le-grand). 1999;45(7):919-930.
2. Tresguerres M, Levin LR, Buck J. Intracellular cAMP signaling by soluble adenylyl cyclase. Kidney Int. 2011;79(12):1277-1288.
3. Zippin JH, Chadwick PA, Levin LR, Buck J, Magro CM. Soluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases. J Invest Dermatol. 2010;130(5):1279-1287.
4. Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature. 1995;374(6521):421-424.
5. Bundey RA, Insel PA. Discrete intracellular signaling domains of soluble adenylyl cyclase: camps of cAMP? Sci STKE. 2004;2004(231):e19.
6. Feng QP, Zuo J, Meng Y, Fang FD. Nuclear localization region in soluble adenylyl cyclase [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005; 27(3):280-284.
7. Feng Q, Zhang Y, Li Y, Liu Z, Zuo J, Fang F. Two domains are critical for the nuclear localization of soluble adenylyl cyclase. Biochimie. 2006;88(3-4):319- 328.
8. Krupinski J. The adenylyl cyclase family. Mol Cell Biochem. 1991;104(1-2): 73-79.
9. Stessin AM, Zippin JH, Kamenetsky M, Hess KC, Buck J, Levin LR. Soluble adenylyl cyclase mediates nerve growth factor-induced activation of Rap1. J Biol Chem. 2006;281(25):17253-17258.
10. Hess KC, Jones BH, Marquez B, et al. The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization. Dev Cell. 2005;9(2):249-259.
11. Zippin JH, Chen Y, Nahirney P. et al. Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains. FASEB J. 2003;17(1):82-84.
12. Zippin JH, Farrell J, Huron D, et al. Bicarbonate-responsive "soluble" adenylyl cyclase defines a nuclear cAMP microdomain. J Cell Biol. 2004;164(4): 527-534.
13. Magro CM, Crowson AN, Desmaze C, Zippin JH. Soluble adenylyl cyclase antibody profile as a diagnostic adjunct in the assessment of pigmented lesions. Arch Dermatol. 2012;148(3):335-344. doi: 10.1001/archdermatol.2011.338.
14. Busam KJ, Chen YT, Old LJ, et al. Expression of Melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22(8):976-982.
15. King R, Googe PB, Weilbaecher KN, Mihm MCJ, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;25(1):51-57.
16. King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 1999;155(3):731-738.
17. Prieto VG, Shea CR. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med. 2011;135(7):853-859.
18. Black WH, Thareja SK, Blake BP, Chen R, Cherpelis BS, Glass LF. Distinction of melanoma in situ from solar lentigo on sun-damaged skin using morphometrics and MITF immunohistochemistry. Am J Dermatopathol. 2011; 33(6):573-578.
19. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163(5):1765-1770.
20. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
21. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002; 46(1):78-84.
22. Bowen AR, Thacker BN, Goldgar DE, Bowen GM. Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna. Dermatol Surg. 2011;37(5):657-663.
23. Hendi A, Wada DA, Jacobs MA, et al. Melanocytes in nonlesional sunexposed skin: A multicenter comparative study. J Am Acad Dermatol. 2011;65(6): 1186-1193.